Protagonist and Takeda Report Positive Phase 3 Results in Rare Blood Cancer at ASCO 2025 VERIFY study meets all endpoints in polycythemia vera, supporting improved hematocrit control, reduced need for phlebotomy, and symptom relief Protagonist Th

#PTGX and #TAK report positive Phase 3 results for rusfertide in rare blood cancer PV at ASCO 2025! The data shows major progress in symptom control and disease management.
#ProtagonistTx #TakedaPharma
#Biotech #ProtagonistTherapeutics #RareDisease #PVResearch
prismmarketview.com/protagonist-...